Amgen Stock Price

-5.01 (-2.13%)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Amgen Inc AMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-5.01 -2.13% 230.71 17:19:17
Close Price Low Price High Price Open Price Previous Close
230.71 230.01 237.4425 236.21 235.72
Bid Price Ask Price Spread News
231.00 231.65 0.65 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
40,141 2,748,196 $ 234.12 $ 643,418,091 2,711,743 177.05 - 264.97
Last Trade Time Type Quantity Stock Price Currency
17:18:49 16 $ 231.35 USD

Amgen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 135.13B 585.69M 584.29M $ 23.36B $ 6.66B 12.89 19.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ 5.80 2.51% - -

more financials information »

Amgen News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AMGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week237.73242.27230.01237.502,445,135-7.02-2.95%
1 Month246.19258.505230.01244.302,591,532-15.48-6.29%
3 Months247.30260.12230.01246.222,623,089-16.59-6.71%
6 Months231.37264.97213.8601240.532,625,280-0.66-0.29%
1 Year203.57264.97177.05228.842,666,85527.1413.33%
3 Years185.99264.97163.31199.482,914,45944.7224.04%
5 Years152.61264.97133.64183.672,953,78278.1051.18%

Amgen Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201019 21:36:05